Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name FLT3 exon 14 ins FLT3 N701K
Gene Variant Detail

FLT3 exon 14 ins (gain of function - predicted)

FLT3 N701K (gain of function - predicted)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins FLT3 N701K hematologic cancer resistant Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 N701K demonstrated resistance to treatment with Xospata (gilteritinib) in culture (PMID: 33780043). 33780043
FLT3 exon 14 ins FLT3 N701K hematologic cancer resistant Midostaurin Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 N701K demonstrated resistance to treatment with Rydapt (midostaurin) in culture (PMID: 33780043). 33780043
FLT3 exon 14 ins FLT3 N701K hematologic cancer resistant Crenolanib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 N701K demonstrated resistance to treatment with Crenolanib (CP-868596) in culture (PMID: 33780043). 33780043
FLT3 exon 14 ins FLT3 N701K hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 N701K in culture (PMID: 33780043). 33780043
FLT3 exon 14 ins FLT3 N701K hematologic cancer sensitive Narazaciclib Preclinical - Cell culture Actionable In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 N701K in culture (PMID: 38641704). 38641704
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia predicted - resistant Gilteritinib + Venetoclax Case Reports/Case Series Actionable In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Venclexta (venetoclax) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia predicted - resistant Azacitidine + Gilteritinib Case Reports/Case Series Actionable In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Vidaza (azacitidine) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia resistant Crenolanib Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Crenolanib (CP-868596) in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia resistant Midostaurin Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Rydapt (midostaurin) in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia sensitive FF-10101 Preclinical - Patient cell culture Actionable In a preclinical study, FF-10101 inhibited viability of a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K hematologic cancer sensitive FF-10101 Preclinical - Cell culture Actionable In a preclinical study, FF-10101 treatment inhibited viability of cells expressing a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132). 37815132